POLEM
Research type
Research Study
Full title
Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer: A phase III randomised study.
IRAS ID
224726
Contact name
Tony Dhillon
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Eudract number
2017-000370-10
Duration of Study in the UK
9 years, 10 months, 29 days
Research summary
In locally advanced colon cancer the standard of care is surgical resection and chemotherapy. Most patients are cured however not all of them are. To improve the cure rate we need to target sub groups of patients who are likely to respond to new drugs. We aim to look at 2 sub groups of patients - Mismatch repair deficient and POLE exonuclease mutant. We think that because of these tumours having a high mutational load, they are likely to respond to a new group of treatments called checkpoint inhibitors. This study will compare the standard of care - surgery and chemotherapy with this plus Avelumab - an immune checkpoint inhibitor. It will be a randomised study.
REC name
London - West London & GTAC Research Ethics Committee
REC reference
18/LO/0165
Date of REC Opinion
9 May 2018
REC opinion
Further Information Favourable Opinion